Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
576.77
-1.28 (-0.22%)
At close: Oct 20, 2025, 4:00 PM EDT
582.00
+5.23 (0.91%)
After-hours: Oct 20, 2025, 7:48 PM EDT
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.68B in the quarter ending June 30, 2025, with 3.62% growth. This brings the company's revenue in the last twelve months to $14.21B, up 5.38% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.21B
Revenue Growth
+5.38%
P/S Ratio
4.35
Revenue / Employee
$940,964
Employees
15,106
Market Cap
59.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
REGN News
- 3 days ago - Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation - GlobeNewsWire
- 5 days ago - Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers - GlobeNewsWire
- 8 days ago - DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss - GlobeNewsWire
- 10 days ago - What If You Were Missing The Value In Regeneron Pharmaceuticals Stock? - Forbes
- 12 days ago - US FDA expands use of Regeneron's Libtayo as add-on treatment for skin cancer - Reuters
- 12 days ago - Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation - GlobeNewsWire
- 13 days ago - 11 Cheap Stocks for a Market That's Too Expensive - Barrons
- 14 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha